SpecialtiesQuestion

How do you approach second-line therapy for patients with PD-L1 positive metastatic TNBC, after progression on sacituzumab govitecan + pembrolizumab?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

How do you select between imlunestrant ± abemaciclib and elacestrant for those with an ESR1 mutation and progressed on AI and CDK4/6 inhibitor for patients with metastatic ER+/HER2- breast cancer?

Would you offer other antibody-drug conjugates to a patient who had a history of G2 trastuzumab deruxtecan-induced pneumonitis that is now resolved?

In previously untreated patients with mTNBC, what is your protocol for prophylactic GCSF use for sacituzumab govitecan?

Does TROP2 expression influence clinical decision-making for TNBC currently?

What are your top takeaways in Breast Cancer from ASCO 2026?

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.